
Kennedy unveils autism research plan using Medicare and Medicaid data
U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. discusses the findings of the Centers for Disease Control and Prevention's (CDC) latest Autism and Developmental Disabilities Monitoring (ADDM) Network survey, during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., April 16, 2025. REUTERS/Elizabeth Frantz
Listen to article
US federal health agencies will develop a national database of autism patients enrolled in Medicare and Medicaid, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr said on Wednesday.
The initiative is aimed at supporting research into the causes of autism spectrum disorder (ASD) and could later expand to include other chronic conditions, according to the department.
Kennedy, who has publicly supported a discredited theory linking vaccines to autism, said the effort would bring "full transparency and accountability" and offer families long-awaited answers.
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on building the platform. It will aggregate real-world data from claims, electronic health records, and wearable devices, HHS said.
The project is part of a broader $50 million research campaign to explore autism's origins—a neurological condition that affects communication, behaviour and learning.
Researchers will be able to study autism diagnoses over time, treatment outcomes, access to care, health disparities, and the economic impact on families.
But not all experts are convinced the new initiative will deliver on its central aim.
'These areas don't address the root causes of autism,' said Dr Helen Tager-Flusberg, director of the Center for Autism Research Excellence at Boston University.
She noted that a similar NIH database had already existed for over a decade but had recently gone offline without explanation.
Eric Rubenstein, another autism researcher at Boston University, said researchers have used Medicare and Medicaid data for years.
It is helpful for studying disparities, he said, but lacks data on environmental exposures—an area Kennedy has pledged to examine.
Kennedy said the new registry would be voluntary and would not collect private information. HHS stated the project would adhere to privacy laws but did not confirm whether data would be anonymised.
NIH, HHS and CMS declined to provide further details on how the data would be used or managed.
Kennedy has said the NIH will determine the causes of autism by September—a timeline most scientists view as unrealistic.
Autism now affects 1 in 31 US children aged eight, according to the Centers for Disease Control and Prevention.
Experts believe a mix of genetic and environmental factors likely contributes to the condition, alongside improved detection and diagnosis.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Express Tribune
2 days ago
- Express Tribune
US CDC COVID vaccine advisor Dr. Lakshmi Panagiotakopoulos resigns: Reuters
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. Photo:REUTER Listen to article Pediatric infectious disease expert Dr Lakshmi Panagiotakopoulos of the US CDC resigned on Tuesday as co-leader of a working group that advises outside experts on COVID-19 vaccines and is leaving the agency, said two sources familiar with the move. Panagiotakopoulos said in an email to work group colleagues that her decision to step down was based on the belief she is "no longer able to help the most vulnerable members" of the US population. In her role at the Centers for Disease Control and Prevention's working group of the Advisory Committee on Immunization Practices, she co-led the gathering of information on topics for presentation. Her resignation comes one week after Health Secretary Robert F Kennedy Jr, a long-time vaccine skeptic who oversees the CDC, the Food and Drug Administration and the National Institutes of Health, said the COVID vaccine for healthy children and healthy pregnant women had been removed from the CDC's recommended immunization schedule. The move was a departure from the process in which ACIP experts meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the agency's director made a final call. The committee had not voted on the changes announced by Kennedy and the CDC does not yet have a permanent director. Two days after Kennedy's announcement, the CDC published a vaccine schedule online saying that COVID-19 vaccines remain an option for healthy children aged 6 months to 17 years when parents and doctors agree that it is needed. It had previously recommended updated COVID vaccines for everyone aged six months and older, following the guidance of the panel of outside experts. Two sources said Panagiotakopoulos did not include a specific reason for her departure. Panagiotakopoulos did not return requests for comment. "Unfortunately for me, this is a personal decision," Panagiotakopoulos wrote in an email to members of the working group that was read to Reuters by a source who received it. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role." The committee is scheduled to meet on June 25-27 and is expected to deliberate and vote on recommendations for use of COVID-19 vaccines, according to one of the sources who was not authorized to speak publicly.


Business Recorder
4 days ago
- Business Recorder
G-B: 1st wild poliovirus case of year reported
ISLAMABAD: Pakistan on Monday reported first wild poliovirus case in District Diamer, Gilgit-Baltistan (G-B), a region which was considered polio virus free for years. According to the Regional Reference Laboratory for Polio Eradication at the National Institute of Health (NIH), a new case of wild poliovirus was reported in District Diamer, Gilgit-Baltistan. This is the first case of wild poliovirus reported from Gilgit-Baltistan and the 11th confirmed case in Pakistan this year. The third nationwide polio vaccination campaign of 2025, which began on 26 May, concluded Sunday. The campaign successfully reached over 45 million children under five years of age across 159 districts, including high-risk areas of the country. Polio is a highly infectious and debilitating disease with no cure. The only way to protect children is through repeated doses of the oral polio vaccine for all children under five as well as the timely completion of all vaccines offered as part of the essential immunisation schedule. The programme is calling on all parents to ensure their children do not miss out on any opportunity to receive polio drops. Every dose of polio vaccine provides an opportunity to further strengthen immunity and protection against lifelong paralysis. With polio still a threat, community support is vital—no child should be missed. Copyright Business Recorder, 2025


Business Recorder
6 days ago
- Business Recorder
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunization schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe COVID-19 for the upcoming immunization campaign. The FDA approved Novavax's COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviors like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.